The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
DIGAMI 2 trial post hoc analysis: Lessons in overinterpretation
December 17th 2008In their post hoc analysis of the DIGAMI 2 (Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2) study, Mellbin and colleagues suggest that insulin therapy after myocardial infarction (MI) may be associated with increased clinical events (not mortality), whereas metformin therapy may be associated with reduced events and sulfonylurea therapy with neutral effects.
Gene Mutation May Reduce Risk of Cardiovascular Disease
Researchers recently announced that they have discovered a "novel gene mutation among the Old Order Amish population that significantly reduces the level of triglycerides in the blood and appears to help prevent cardiovascular disease."
Advanced CT Offers Better Option for Detecting Coronary Artery Blockages
New research into the capabilities of advanced computed tomography (CT) published recently in the New England Journal of Medicine (http://content.nejm.org/cgi/content/abstract/359/22/2324) revealed "solid evidence that the newer, more powerful 64-CT scans can easily and correctly identify people with major blood vessel disease and is nearly as accurate as invasive coronary angiography."
Is Hormone Therapy Dangerous for Women with Existing Heart Risk?
Researchers from the University of Michigan School of Public Health reported last month in the Archives of Internal Medicine that hormone therapy may produce adverse heart health effects even in women who begin treatment within the recommended timeframe post-menopause.
Hypertension a Silent Killer in Young African American Men
Study results published in the October 2008 issue of the American Journal of Physiology � Heart and Circulatory Physiology reveal that "young African American men have greater central [blood pressure] despite comparable brachial [blood pressure] when compared with young white men."
High Triglycerides Linked to Elevated Stroke Risk
According to study results published recently in JAMA, elevated nonfasting triglyceride levels, previously associated with an increased risk for heart attack, also appear to be associated with an increased risk for ischemic stroke.
Can You Use Your Own Stem Cells to Treat Heart Failure?
Researchers at the Methodist Hospital in Houston, TX; Baylor University Medical Center in Dallas, TX; and The University of Utah School of Medicine in Salt Lake City, UT, are enrolling patients in a new clinical trial designed to help find the answer to that question.
Impact of diabetes development on atrial fibrillation in hypertensive patients
Patients with new-onset diabetes mellitus in the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial had an increased incidence of atrial fibrillation compared with patients without diabetes. Clustering of risk factors or the presence of dysglycemia may make the heart more susceptible to arrhythmias.
Insulin as a strategy to optimize glycemic control in patients with type 2 diabetes
November 14th 2008Treatment of type 2 diabetes should achieve and maintain euglycemia, thereby preventing complications from this progressive disease. Current antidiabetic therapies should be a part of a multimodal management program that includes diet, exercise, and blood pressure and lipid control. Oral antidiabetic drugs are still first-line therapy for type 2 diabetes, but intensification of therapy, including starting insulin, should occur every 2 to 3 months as needed to achieve euglycemia. The first insulin added is typically a basal insulin, which is effective in lowering fasting plasma glucose (FPG). A persistently elevated glycated hemoglobin (HgbA1C) level despite near or complete normalization of FPG, however, indicates postprandial hyperglycemia. In these cases, the addition of bolus insulin is required to reduce postprandial glucose (PPG). Several approaches to initiate and titrate insulin can be used based on FPG, PPG, HgbA1C, and patient factors.
Glycemic control and CVD outcomes: Randomized clinical trials in 2008
November 14th 2008The relationship of glucose levels to cardiovascular disease (CVD) risk, especially coronary heart disease (CHD), in observational data sets has been the subject of several studies. These studies have shown that the relationship between fasting (and postprandial glucose) and CHD risk is continuous and graded, and that this relationship extends below the currently defined threshold for diagnosing diabetes mellitus. The assumption has been that glycemic control in patients with diabetes mellitus should favorably affect CVD outcomes in randomized clinical trials; however, the results of several large trials have not consistently confirmed this hypothesis. In fact, ACCORD (Action to Control Cardiovascular Risk in Diabetes) data suggest a small increased risk in mortality for patients at high risk for CHD events.
Alogliptin: The newest agent to fight the diabetes pandemic
November 14th 2008According to the American Diabetes Association (ADA), 23.6 million children and adults have diabetes (8% of the US population) and another 5.7 million cases remain undiagnosed. Epidemiologists predict that these statistics will double by 2030, further taxing the healthcare system. Medical expenditures are approximately 2.3 times higher for diabetic versus nondiabetic patients, and the annual cost of diabetes is estimated to be $116 billion.
New Guidelines Released on the Management of Congenital Heart Disease in Adults
The American College of Cardiology and the American Heart Association announced the joint release of a comprehensive set of new practice guidelines on the management of adults with congenital heart disease.